Article

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-cell Lymphoma in Canada

2025-01-28

Abstract excerpt

CAR-T cell therapy has significantly improved outcomes for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but challenges such as limited resources, manufacturing timelines, and notable toxicities persist. Bispecific antibodies (BsAbs), including glofitamab and epcoritamab have demonstrated promising efficacy and represent a new treatment option in patients who are unsuitable for...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fd477453-04fe-56c2-8d0b-4e4715204294
DOI: 10.20944/preprints202501.1882.v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-cell Lymphoma in CanadaDOI 10.20944/preprints202501.1882.v2Read

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasSemantic proximity Read

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read

Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic PopulationSemantic proximity Read

Burkitt lymphoma: bridging the gap between advances in molecular biology and therapySemantic proximity Read

[Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].Semantic proximity Read

Double-Hit Large B Cell Lymphoma.Semantic proximity Read

Classifying DLBCL Subtypes for Optimal Treatment.Semantic proximity Read

Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphomaSemantic proximity Read

Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.Semantic proximity Read

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity Read